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Summary
Background: Dumping syndrome, a common complication of esophageal, gas-
tric or bariatric surgery, includes early and late dumping symptoms. Early dumping
occurs within 1 h after eating, when rapid emptying of food into the small intestine
triggers rapid fluid shifts into the intestinal lumen and release of gastrointestinal
hormones, resulting in gastrointestinal and vasomotor symptoms. Late dumping
occurs 1–3 h after carbohydrate ingestion, caused by an incretin-driven
hyperinsulinemic response resulting in hypoglycemia. Clinical recommendations
are needed for the diagnosis and management of dumping syndrome.
Methods: A systematic literature review was performed through February 2016.
Evidence-based medicine was used to develop diagnostic and management strate-
gies for dumping syndrome.
Results: Dumping syndrome should be suspected based on concurrent presenta-
tion of multiple suggestive symptoms after upper abdominal surgery. Suspected
dumping syndrome can be confirmed using symptom-based questionnaires,
glycemia measurements and oral glucose tolerance tests. First-line management
of dumping syndrome involves dietary modification, as well as acarbose treat-
ment for persistent hypoglycemia. If these approaches are unsuccessful, somato-
statin analogues should be considered in patients with dumping syndrome and
impaired quality of life. Surgical re-intervention or continuous enteral feeding
may be necessary for treatment-refractory dumping syndrome, but outcomes
are variable.
Conclusions: Implementation of these diagnostic and treatment recommenda-
tions may improve dumping syndrome management.
Keywords: dumping syndrome, hyperinsulinemic hypoglycemia, pasireotide, so-
matostatin analogue.
Abbreviations: GLP, glucagon-like peptide; GIP, glucose-dependent insulinotropic
polypeptide or gastric inhibitory polypeptide; VAS, visual analogue scale; sst, so-
matostatin receptor subtype; OGTT, oral glucose tolerance test; GI, gastrointesti-
nal; VIP, vasoactive intestinal peptide; LAR, long-acting release.
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Introduction
Dumping syndrome is a frequent complication of esopha-
geal, gastric or bariatric surgery. Alterations in gastric
anatomy or interference with its intrinsic innervation dis-
turb gastric emptying mechanisms and allow a substantial
amount of undigested food to reach the small intestine too
rapidly (1,2). Dumping syndrome is not a single disease en-
tity but, instead, consists of a constellation of symptoms
that can be categorized as early dumping or late dumping
symptoms (1,2). Early dumping syndrome occurs within
the first hour after a meal. Because of the hyperosmolality
of the food, rapid fluid shifts occur from the plasma com-
partment into the intestinal lumen, resulting in hypotension
and a sympathetic nervous-system response. Early dumping
is characterized by gastrointestinal (GI) symptoms such as
abdominal pain, bloating, borborygmi, nausea, and diar-
rhoea, and vasomotor symptoms such as fatigue, desire to
lie down after meals, flushing, palpitations, perspiration,
tachycardia, hypotension, and, rarely, syncope (1,2). In con-
trast, late dumping usually occurs 1 to 3 h after a meal and
is a result of an incretin-driven hyperinsulinemic response
after carbohydrate ingestion. Hypoglycemia-related symp-
toms are related to neuroglycopenia (fatigue, weakness,
confusion, hunger and syncope) and autonomic/adrenergic
reactivity (perspiration, palpitations, tremor and irritability)
(1,2). Moreover, dumping syndrome cannot always be
discretely separated into early and late dumping symptoms
but, instead, is an entire disease spectrum whereby patients
can develop early dumping, late dumping or both. Further-
more, early dumping symptoms may have resolved in some
patients before late dumping symptoms present.
The prevalence of early and late dumping symptoms
depends on the type and extent of surgery, as well as the def-
inition of dumping syndrome used by study investigators.
Thus, considerable heterogeneity may exist among different
study populations, making it difficult to accurately compare
results. Therefore, in acknowledgement of these differences,
this systematic review includes a description of the study
population where relevant. Dumping syndrome has been
reported to occur in approximately 20% of patients who
undergo vagotomy with pyloroplasty, in up to 40% of pa-
tients after Roux-en-Y gastric bypass or sleeve gastrectomy,
and in up to 50% of patients who undergo esophagectomy
(3–7). Dumping syndrome has also been reported to occur
after Nissen fundoplication in children and in adults (8,9).
In recent years, bariatric surgery has become the leading
cause of postoperative dumping syndrome (10). Bariatric
surgery results in major alterations to the anatomy and
function of the GI tract (11). Various types of bariatric
surgery have been used in recent years, including the Roux-
en-Y gastric bypass, sleeve gastrectomy, biliopancreatic
diversion, vertical banded gastroplasty and laparoscopic
adjustable gastric band. The sleeve gastrectomy, vertical
banded gastroplasty and the laparoscopic adjustable gastric
band are restrictive procedures, in which the volume capac-
ity of the proximal stomach is reduced. The Roux-en-Y
gastric bypass and biliopancreatic diversion are considered
malabsorptive procedures because they interfere with the
normal digestion and absorption of food (11). After bariatric
surgery, dumping syndrome has mainly been reported in pa-
tients who underwent Roux-en-Y gastric bypass and inter-
ventions involving partial gastrectomy (11). Among 450
patients who underwent a Roux-en-Y gastric bypass or
sleeve gastrectomy, approximately one-third (34.2%) re-
ported postoperative symptoms consistent with postpran-
dial hypoglycemia (12). The mechanisms underlying
dumping syndrome after bariatric surgery are numerous
and remain to be fully elucidated (11).
Early dumping syndrome is the most frequent type of
dumping syndrome and may occur in isolation or in associ-
ation with late symptoms. Isolated late dumping (hypogly-
cemia as the only symptom) affects up to 25% of patients
(6,13). Symptoms suggestive of early and late dumping
syndrome may be severe and persist in some patients many
years after surgery (7,14). Among 129 patients who
underwent gastric bypass surgery, 12% reported severe
fatigue after eating (half were so tired that they needed to
lie down), 7% reported severe nausea and 6% severe
fainting (14). Approximately, 12% had persistent dumping
symptoms 1 to 2 years after surgery, especially postprandial
fatigue necessitating lying down; 7% had persistent nausea
and 6% had persistent fainting (14).
Dumping syndrome may result in either weight loss or
weight gain. In severe cases, dumping syndrome is associated
with a substantial reduction in quality of life and significant
weight loss as a result of avoidance of food intake (15).
Patients with severe dumping syndrome may experience
weight loss of up to 30% of their preoperative weight (16).
However, although it has previously been suggested that
dumping symptoms might be essential for weight loss after
bariatric surgery, a prospective series demonstrated that
weight loss after Roux-en-Y gastric bypass was not depen-
dent on the presence of dumping symptoms, and other stud-
ies suggest that some patients with dumping syndrome may
exhibit weight gain (5,17,18). Furthermore, a Swedish
nationwide cohort study of 5,040 post-gastric bypass
patients demonstrated that approximately 1% were hospi-
talized for hypoglycemia and/or related disorders at a
median of 2.7 years after surgery (19). Patients were also at
increased risk for confusion, syncope, epilepsy and seizures
after gastric bypass surgery (19). Symptoms can also be emo-
tionally distressing, leading to anxiety and apprehension.
Because of the large number of patients undergoing bariatric
surgery, it is important to educate clinicians about how to
recognize and manage dumping syndrome. Therefore, this
systematic review was conducted to develop uniform guid-
ance about the management of dumping syndrome.
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Search methodology
A literature search of the PubMed database was performed
to identify relevant literature published through February
2016. Search terms included ‘dumping syndrome’ combined
with ‘symptoms,’ ‘pathophysiology,’ ‘management,’ ‘diet,’
‘pectin,’ ‘guar gum,’ ‘glucomannan,’ ‘acarbose,’ ‘somato-
statin analogue,’ ‘octreotide,’ ‘lanreotide,’ ‘pasireotide,’
‘diazoxide,’ ‘nifedipine,’ ‘glucagon-like peptide 1 (GLP-1)
receptor antagonist,’ ‘surgery’ and ‘continuous enteral feed-
ing.’ The reference lists from retrieved articles were also
reviewed for relevant publications. The search results were
manually reviewed to eliminate commentaries and
correspondence/letters related to the clinical study publica-
tions. Applying these quantitative and qualitative filters
reduced the search results to approximately 160 potentially
relevant citations. Each of the selected publications was
reviewed for management approaches for dumping syn-
drome, and consensus recommendations were developed
by an interdisciplinary team (endocrinologist, gastroenterol-
ogist, nutritionist and bariatric surgeon) to provide uniform
practical guidance to the different specialists involved in the
management of dumping syndrome. A systematic review of
diagnostic approaches for dumping syndrome was not per-
formed, but the most widely used approaches are described
briefly herein. A more in-depth review of the diagnosis of
dumping syndrome has recently been published (20).
Pathophysiology
The pathophysiological mechanisms involved in dumping
syndrome are incompletely understood. Relatively few
recent studies have been devoted to elucidating the mecha-
nisms involved in early and late dumping syndromes, and
much of our current knowledge is based on older literature
(21). Symptoms of early and late dumping syndrome appear
to be caused by distinct pathophysiological mechanisms.
Early dumping
Several concurrent phenomena contribute to the develop-
ment of early dumping symptoms (3,22–25). Gastric
surgery reduces gastric volume or removes the barrier func-
tion of the pylorus, resulting in the rapid delivery of a sub-
stantial amount of undigested solid food to the small
intestine, thereby bypassing the larger part of the stomach
(Fig. 1) (1). Esophageal surgery may also impair gastric re-
tentive capacity because the accompanying vagotomy
causes rapid liquid emptying. Hyperosmolar nutrients in
the small bowel presumably cause a shift of fluid from the
intravascular compartment (i.e. plasma) to the intestinal
lumen, resulting in a reduction in plasma volume, tachycar-
dia, and, rarely, syncope. Movement of fluid into the small
bowel may also cause distention and contribute to cramp-
like contractions, bloating and diarrhoea. Whether this fluid
shift contributes to the pathophysiology of dumping syn-
drome or is mainly a consequence of this process remains
unknown. In favour of the latter interpretation, intravenous
fluid substitution is not effective in preventing early dump-
ing symptoms (26). Another important mechanism involved
in the pathophysiology of early dumping syndrome (and
also late dumping syndrome as described below) involves
the increased release of multiple GI hormones including
vasoactive agents (e.g. neurotensin and vasoactive intestinal
peptide [VIP]), incretins (e.g. gastric inhibitory polypeptide
[GIP] and GLP-1), and glucose modulators (e.g. insulin
and glucagon) (22,24,25). Enhanced release of these GI
hormones may induce discoordinated GI motility and
inhibit secretion, as well as elicit hemodynamic effects; for
example, neurotensin and vasoactive intestinal polypeptide
induce splanchnic vasodilation that results in hypotension
and systemic hemoconcentration (27).
Late dumping
In contrast to the multiple pathophysiologic factors in-
volved in early dumping syndrome, the pathophysiology
of late dumping is largely attributable to the development
of hyperinsulinemic or reactive hypoglycemia (3,22–25).
Rapid delivery of undigested carbohydrates to the small
intestine results in high glucose concentrations that induce
a hyperinsulinemic response, resulting in subsequent hypo-
glycemia and related late dumping symptoms (28). Enteral
glucose administration is known to induce enhanced insulin
release relative to intravenous administration, a process
known as the incretin effect. Two GI hormones are believed
to play a pivotal role in the incretin effect: glucose-
dependent insulinotropic polypeptide or gastric inhibitory
polypeptide and GLP-1. An increased GLP-1 response has
been reported in patients after gastric surgery, and a positive
correlation has been observed between increasing GLP-1
levels and insulin release (29). An additional study suggests
that GLP-1 analogues may actually stabilize glucose levels
in patients with postprandial hypoglycemia after gastric
bypass surgery (30). Therefore, an exaggerated endogenous
GLP-1 response appears to be the key mediator of the
hyperinsulinemic and hypoglycemic effect that is character-
istic of late dumping syndrome (18,29). However, the
precise mechanism by which GLP-1 contributes to glucose
homeostasis and late dumping syndrome is likely to be
complex and remains to be fully elucidated.
Diagnosis
Population at risk
Dumping syndrome should be suspected based on the
concurrent presentation of multiple suggestive symptoms
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in patients who have undergone gastric or esophageal
surgery (1). A carefully obtained medical history and
thorough symptom evaluation are very important for the ac-
curate diagnosis of dumping syndrome. Profound fatigue af-
ter meal ingestion, with the need to lie down, is an important
clinical clue. Various approaches can be used to confirm the
presence of dumping syndrome, including symptom-based
questionnaires, glycemia monitoring, oral glucose challenge
testing and gastric emptying studies. An additional diagnos-
tic evaluation may also be necessary to exclude conditions
that can present with similar symptoms (e.g. postoperative
complications, strictures, adhesions and insulinoma). Hypo-
glycemia unawareness may develop as a result of recurrent
hypoglycemia, making it even more difficult to diagnose late
dumping syndrome in patients who have undergone gastric
bypass surgery (20).
Symptom-based questionnaires
Symptom-based questionnaires, such as the Sigstad’s score
and the Arts’ dumping questionnaire can be used to identify
patients with clinically meaningful dumping symptoms.
Sigstad’s score was developed to separate patients with or
without postoperative dumping syndrome in the era of
peptic ulcer surgery (17), while Arts’ dumping questionnaire
was designed to differentiate between early and late dump-
ing symptoms. The Sigstad’s scoring system assigns points
to each dumping symptom, and the total points are used
to calculate a diagnostic index (31). A diagnostic index >7
is suggestive of dumping syndrome whereas a score <4
suggests that other diagnoses should be considered. Patients
receive an oral glucose tolerance test (OGTT) prior to using
the Sigstad’s scoring system to score and grade symptom
severity. The primary focus of the Sigstad’s scoring system
is to identify early dumping by diagnosing signs and symp-
toms such as a high pulse rate or increased haematocrit
indicative of hypovolemia. The diagnostic accuracy of the
Sigstad’s scoring questionnaire in bariatric patients or after
upper GI cancer surgery has not been established (7). Arts
et al. developed a dumping-severity score in which symp-
toms of early and late dumping (eight and six symptoms,
respectively) were scored on a 4-point Likert scale (15). This
Figure 1 Pathophysiology of dumping syndrome. Abbreviations: GIP, gastric inhibitory polypeptide; GLP-1, glucagon-like peptide-1; VIP, vasoactive in-
testinal peptide.
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questionnaire has been tested on patients with early and late
dumping, and was shown to be effective at discriminating
between the two sets of symptoms and was responsive to
somatostatin analogue therapy, but was never formally
validated (15). A relatively recent report also describes the
use of a visual analogue scale (VAS) survey to evaluate early
and late dumping syndromes in more than 1,000 patients
after gastrectomy for gastric cancer (32). This survey used
a very low cutoff for dumping complaints (VAS score
>10mm), and a single item on the questionnaire was suffi-
cient to label patients as symptomatic for late dumping (32).
Glycemia measurements
Single plasma glucose measurements, whether scheduled or
random, can be performed during clinic visits after gastric
or esophageal surgery. Although the diagnostic value of a
single glucose measurement is low, its clinical value increases
when evaluated in conjunction with late dumping symp-
toms. To date, no definitive guidance regarding cutoff values
for plasma glucose has been established, but some clinicians
consider plasma glucose concentrations <2.8mmol/L
(50mg/dL) to be indicative of post-gastric bypass hypoglyce-
mia, whereas others regard levels <3.3mmol/L (60mg/dL)
diagnostic of hypoglycemia (33). Capillary glucose measure-
ments (finger prick) are not considered valid because of their
lack of accuracy in the hypoglycemic range. Continuous
glucose monitoring may be beneficial in complex cases of
dumping syndrome (34–36).
Provocative testing
Clinical suspicion of dumping syndrome can be confirmed
using provocative tests such as the OGTT or mixed-meal
tolerance test (37). In the glucose tolerance test, patients
with suspected dumping syndrome ingest 50 g or 75 g of
glucose in solution after an overnight fast. Blood glucose
concentrations, haematocrit, pulse rate and blood pressure
are measured before and at 30-min intervals up to
180min after ingestion. The OGTT is considered positive
for early dumping based on the presence of an early
(30min) increase in haematocrit >3% or an increase in
pulse rate >10 beats/min after 30min, the latter being
regarded as the most sensitive indicator of early dumping
syndrome (1). Test results are positive for late dumping
based on the development of late (60–180min
postingestion) hypoglycemia (1). In the mixed-meal toler-
ance test, patients with suspected dumping syndrome ingest
a mixed meal containing carbohydrates, fats and proteins
after an overnight fast (18,38). Blood samples are collected
before meal ingestion and at 30-min intervals for up to 2 h
afterward to monitor glycemic and insulin profiles. The
mixed-meal tolerance test is considered positive for late
dumping syndrome in patients who develop hypoglycemia
between 60 and 180min after meal ingestion.
The use of provocative testing to diagnose dumping syn-
drome is associated with several challenges. Provocative
testing can be difficult in patients with small gastric pouches
as a result of gastric or bariatric surgical procedures.
Furthermore, the OGTT frequently detects post-gastric
bypass hypoglycemia in patients with and without symp-
toms, as well as in healthy individuals (20). Therefore, the
diagnostic accuracy of this test is low and normative values
have not been firmly established (20). As a result, clinical
practice guidelines for adult hypoglycemic disorders devel-
oped by the Endocrine Society do not support the use of
the OGTT for diagnosing postprandial hypoglycemia (39).
The mixed meal tolerance test holds promise as a more
physiologic stimulation test for the detection of post-gastric
bypass hypoglycemia (20,40). Some studies demonstrate
improved specificity of this test in asymptomatic patients;
however, normative values have not been established for
healthy individuals (20). Further validation of the mixed
meal tolerance test is needed in patients with and without
hypoglycemia symptoms, as well as in healthy individuals.
Because there is currently no optimal approach for the diag-
nosis of dumping syndrome, (20) provocative testing is still
commonly used in some countries to diagnose hypoglyce-
mia in the safety of a medical testing facility.
Gastric emptying studies
The rate of gastric emptying may also be used to confirm a
diagnosis of dumping syndrome. A gastric emptying scintig-
raphy test involves eating a bland meal that contains a small
amount of radioactive material, and measuring the rate of
gastric emptying at hourly intervals until 4 h after the meal.
However, gastric emptying studies generally have low sensi-
tivity and specificity, probably because the process of rapid
gastric emptying occurs soon after ingestion, a phase that is
not adequately assessed in most studies. Furthermore, the
duration of the entire study of up to 4 h is integrated into
a single value (half emptying time), which may neutralize
the rapid initial emptying effect (3,15,37).
Differential diagnosis
A differential diagnosis should also be considered in
patients with suspected dumping syndrome.
Early dumping
Symptoms of cramp-like contractions, bloating and
diarrhoea in patients with a history of upper GI surgery
may also occur as a consequence of complications such as
stenosis, fistula formation, adhesions and ischemia. A
marginal ulcer or gastritis is generally characterized by pain
during meals, acid reflux, and nausea, and the diagnosis can
72 Dumping syndrome A. P. van Beek et al. obesity reviews
© 2016 The Authors.Obesity Reviews published by John Wiley & Sons Ltd
on behalf of World Obesity Federation
Obesity Reviews 18, 68–85, January 2017
be confirmed via gastroscopy. Symptoms of stenosis or
anastomoses are similar to symptoms of marginal ulcer
accompanied by dysphagia, and the diagnosis can be
confirmed via gastroscopy or a barium or gastrografin
swallow. Internal herniation generally results in pain,
sometimes colic pain, a sensation of fullness quickly after
meals, sometimes ileus and vomiting and no vegetative
symptoms. A diagnosis of internal herniation can be
confirmed via computed tomography or diagnostic laparos-
copy. The main characteristics of obstipation are a feeling of
fullness, pain and defecation only once in 3 days. Symptom-
atic gallstone disease is characterized by colicky pain
attacks, with an urge to move, nausea, and, often, vomiting.
Pain generally lasts for at least 1 h. Diagnoses can be
confirmed with an ultrasound showing gallbladder stones
and blood testing confirming liver function abnormalities
after colic.
Late dumping
A differential diagnosis of hyperinsulinemic hypoglycemia is
important in patients with late dumping symptoms. Late
dumping occurs during the postprandial period (1-3 h after
eating). In contrast, an insulinoma, which is extremely rare,
should be considered if fasting hypoglycemia occurs (i.e. not
provoked by a meal) (41,42). A fast of up to 72 h (usually
48 h) in a supervised hospital setting to assess hypoglycemia
and the pathological lack of decrease in insulin secretion
may be indicated in case of doubt (39,41). Surreptitious
use of glucose-lowering medications (e.g. sulfonylurea
derivatives or insulin) should also be excluded in each case,
which can be determined via a sulfonylurea and C-peptide
assay, respectively. In the case of hypoglycemia resulting
from exogenous insulin injection, C-peptide levels are
inappropriately low at the time of hyperinsulinemic hypo-
glycemia. Finally, postprandial syncope may be similar to
loss of consciousness, and the two conditions may be diffi-
cult to differentiate, especially in elderly patients.
Treatment
Treatment approaches for dumping syndrome include die-
tary modifications, pharmacologic interventions and, possi-
bly, surgical re-intervention or continuous tube feeding.
Some treatments are indicated solely for late dumping (e.g.
acarbose), whereas others are potentially beneficial for both
early and late dumping (e.g. somatostatin analogues). The
effectiveness of some of these approaches has not been
clearly established as most studies included relatively few
patients and were not adequately controlled. The level of
evidence and grade of recommendation, as described in
Table 1, supporting the use of each of these approaches in
dumping syndrome is provided.
Dietary modification (level of evidence: III; grade of
recommendation: B)
Dietary modification is the initial approach used to manage
dumping syndrome and is usually beneficial for a majority
of patients (3,10,16,43–47). Therefore, proper patient edu-
cation about dietary modification is very important and
should be repeated before all subsequent treatment ap-
proaches. In addition, clinicians caring for patients after
bariatric surgery should be aware of dietary approaches
for the management of dumping syndrome. Clinicians
should advise patients with dumping syndrome to reduce
the amount of food consumed at each meal. Patients should
also delay fluid intake until at least 30min after meals. Rap-
idly absorbable carbohydrates should be eliminated from
the diet to prevent late dumping symptoms such as hypogly-
cemia. Instead, patients should be advised to eat a diet
consisting of high-fibre and protein-rich foods; consump-
tion of fruit and vegetables should be encouraged whereas
alcoholic beverages are better avoided. Patients should also
eat slowly and chew well. Education about the glycemic in-
dex of different foods may also be helpful for patients with
Table 1 Levels of evidence and grades of recommendation
Level of evidence Type of evidence
I Evidence from meta-analysis of multiple, well-designed, controlled studies (randomized trials with low false-positive
and low false-negative errors)
II Evidence from at least 1 well-designed, quasi-experimental study (randomized trials with high false-positive and high
false-negative errors)
III Evidence from well-designed, quasi-experimental studies (nonrandomized, controlled, single-group, pre–post, cohort
and time or matched case–control series)
IV Evidence from well-designed, non-experimental studies (comparative and correlational descriptive and case studies)
V Evidence from case reports
Grade of recommendation Level of evidence
A Level I evidence or consistent findings from multiple studies (level II, III or IV)
B Level II, III or IV evidence with generally consistent findings
C Level II, III or IV evidence with inconsistent findings
D Little or no systematic empirical evidence
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dumping syndrome. If these recommendations are not effec-
tive or are not followed properly, patients should be advised
to lie down for 30min after meals to delay gastric emptying
and reduce the symptoms of hypovolemia (1,16).
Dietary supplements (level of evidence: III; grade of
recommendation: C)
Dietary supplements that increase the viscosity of food
(e.g. guar gum, pectin and glucomannan) slow the rate of
gastric emptying and delay glucose absorption. A number
of short-term studies involving the ingestion of up to 15 g
of guar gum or pectin with each meal have demonstrated
the efficacy of these dietary supplements in slowing gastric
emptying, reducing GI hormone release, improving hyper-
glycemia and controlling dumping symptoms (Table 2)
(48–57). A single study reported that glucomannan signifi-
cantly improved glucose tolerance but had no effect on glu-
cose absorption in children with dumping syndrome who
underwent various types of gastric surgery (57). However,
the palatability and tolerability of many dietary supplements
are poor. Because dietary supplements are high in fibre, some
patients may experience gas and bloating. Furthermore,
dietary recommendations to delay fluid intake until at least
30min after meals means that consumption of viscous,
gel-forming dietary supplements with dry food may pose a
choking hazard and cause bowel obstruction as a result of
a delay in the transit of food through the GI tract.
Pharmacologic intervention
Pharmacologic intervention plays an important role in the
management of dumping syndrome in patients who fail to
respond to dietary modification. Several studies have evalu-
ated acarbose or somatostatin analogues in patients with
dumping syndrome (described in detail below). The efficacy
and tolerability of other pharmacologic agents have mainly
been presented as case reports, and clinical evidence
supporting their use in dumping syndrome is more limited.
Acarbose (level of evidence: III; grade of recommendation:
B)
Acarbose is an α-glycosidase hydrolase inhibitor that slows
carbohydrate digestion in the small intestine, thus blunting
postprandial hyperglycemia and subsequent hypoglycemia.
Several small studies demonstrated that acarbose improved
glucose tolerance, reduced GI hormone release, reduced
the incidence of hypoglycemia and improved symptoms in
patients with dumping syndrome (Table 3) (8,34,53,58–66).
However, the use of acarbose as a treatment approach for
Table 2 Summary of pectin, guar Gum and glucomannan studies in dumping syndrome
Study Design Treatment Results
Jenkins et al. (48) Case series N = 9 Pectin 14.5 g, single
administration before OGTT1
• Normalized glycemia
• Prevented hypoglycemic symptoms
Jenkins et al. (49) Case series N = 11 Pectin 14.5 g, single
administration before OGTT1
• Significantly reduced high postprandial
levels of glucose, insulin and enteroglucagon
• Reduced hypoglycemia
Leeds et al. (50) Case series N = 12 Pectin 15 g, single administration
before OGTT1
• Improved glycemia and vasomotor symptoms
• Reduced insulin levels
• Prolonged gastric emptying
Lawaetz et al. (51) Case series N = 4 Pectin 15 g, single administration
before OGTT1
• Reduced vasomotor symptoms
• Decreased levels of insulin, glucagon,
neurotensin and GIP
• Slowed initial gastric emptying
Andersen et al. (52) Case series N = 5 Pectin 5 g, single administration
before meal1
• No effect on symptoms or gastric emptying
rate
Speth et al. (53) Double-blind, randomized,
controlled study N = 9
Acarbose 50–100 mg, pectin
4.2 g, acarbose 50 mg plus
pectin 4.2 g, placebo, after
standard breakfast
• Acarbose and acarbose plus pectin inhibited
postprandial hyperglycemia and hypoglycemia
• Acarbose plus pectin inhibited hyperinsulinemia
• Acarbose, pectin and combination reduced
hypoglycemic symptoms
Harju et al. (54) Double-blind, controlled
study N = 11
Guar gum 5 g or placebo with
meals for 1 week
• Improved dumping symptoms
Harju et al. (55) Double-blind, controlled
study N = 11
Guar gum 5 g or placebo after
a meal
• Slowed gastric emptying
Harju et al. (56) Case series N = 16 Guar gum 5 g with a glucose
challenge meal1
• Improved symptoms
Kneepkens et al. (57) Case series N = 8 Glucomannan 1.3 g before OGTT1 • Significantly improved glucose tolerance
• No effect on glucose absorption
1Efficacy was determined by comparing assessments performed before and after treatment.
Abbreviations: GIP, glucose‑dependent insulinotropic polypeptide or gastric inhibitory polypeptide; OGTT, oral glucose tolerance test.
74 Dumping syndrome A. P. van Beek et al. obesity reviews
© 2016 The Authors.Obesity Reviews published by John Wiley & Sons Ltd
on behalf of World Obesity Federation
Obesity Reviews 18, 68–85, January 2017
dumping syndrome is limited by the fact that it affects only
late dumping symptoms and may result in side effects related
to carbohydrate maldigestion, such as bloating, flatulence
and diarrhoea.
Somatostatin analogues (level of evidence: II; grade of
recommendation: A)
Somatostatin analogues are an effective treatment option for
patients with well-established dumping syndrome who fail
to respond to and/or do not tolerate initial dietary modifica-
tion and acarbose treatment. Somatostatin analogues target
various steps in the pathophysiology of dumping syndrome,
including delaying gastric emptying, delaying transit through
the small intestine, inhibiting the release of GI hormones,
inhibiting insulin secretion and inhibiting postprandial
vasodilation (15,67–78). Somatostatin inhibition of GLP-1
secretion is mediated via activation of the somatostatin recep-
tor subtype (sst) 5, with a lesser effect through sst2 (79). Both
short-acting and long-acting formulations of somatostatin
analogues have demonstrated efficacy by slowing gastric
emptying, improving hypoglycemia and reducing early and
late dumping symptoms (Table 4) (15,66,80–95).
Table 3 Summary of acarbose studies in dumping syndrome
Study Design Treatment Results
McLoughlin et al. (58) Case series N = 10 Acarbose 100 mg or placebo single
administration before OGTT
• Improved glycemia and symptoms
• Reduced increase in plasma levels of
GIP and insulin
• No change in gastric emptying rate
Gerard et al. (59) Double-blind, randomized,
controlled study N = 24
Acarbose 100 mg or placebo single
administration before OGTT
• Improved reactive hypoglycemia
• Reduced increase in plasma levels of
insulin
• Inhibited glucose-induced glucagon
suppression
Lyons et al. (60) Double-blind, randomized,
controlled study N = 13
Acarbose 50 mg or placebo single
administration before standard
breakfast
• Significantly attenuated hyperglycemia
• Reduced increase in plasma levels
of GIP, enteroglucagon and insulin
• No effect on plasma levels of
neurotensin, VIP and somatostatin
• No significant effect on symptoms
n = 9 Acarbose 50 mg TID or placebo
for 1 month
• No significant reduction in the
number or severity of dumping attacks
• Most patients preferred acarbose
Hasegawa et al. (61) Case series N = 6 Acarbose 50–100 mg TID
before meals for 1 month1
• Attenuated glucose and insulin
fluctuations
• Improved dumping symptoms
Ozgen et al. (62) Case series N = 21 Acarbose 150 mg/day before meals
for 2 weeks and 300 mg/day for
the remainder of the 3-month
treatment period1
• Reduced early hyperglycemic and
hyperinsulinemic response
• Reduced reactive hypoglycemia
Ng et al. (8) Case series N = 6 Acarbose 12.5 mg before a meal1 • Improved postprandial hypoglycemia
De Cunto et al. (63) Case series N = 4 Acarbose 25–100 mg before meals1 • Stabilized postprandial glucose
Valderas et al. (64) Case series N = 8 Acarbose 100 mg before a meal1 • Avoided postprandial hypoglycemia
• Reduced hyperinsulinemic response
• Reduced GLP-1 secretion
Ritz et al. (34) Case series N = 8 Acarbose 50–100 mg, TID
for 6 weeks1
• Eliminated dumping symptoms
• Improved CGM profile
Speth et al. (53) Double-blind, randomized,
controlled study N = 9
Acarbose 50–100 mg, pectin 4.2 g,
acarbose 50 mg plus pectin 4.2 g,
placebo, after standard breakfast
• Acarbose and acarbose plus pectin
inhibited postprandial hyperglycemia and
hypoglycemia
• Acarbose plus pectin inhibited
hyperinsulinemia
• Acarbose, pectin and combination
reduced hypoglycemic symptoms
Vilarrasa et al. (66) Multicenter, retrospective,
systematic case series N = 22
Alpha-glucosidase inhibitors2
50 mg/8 h orally
• 4 patients (18%) had a partial response3
1Efficacy was determined by comparing assessments performed before and after treatment.
2Alpha-glucosidase inhibitor not specified.
3Fifty percent reduction in the number and severity of hypoglycemic events.
Abbreviations: CGM, continuous glucose monitoring; GIP, glucose‑dependent insulinotropic polypeptide or gastric inhibitory polypeptide; GLP-1, gluca-
gon-like peptide 1; OGTT, oral glucose tolerance test; TID, three times per day; VIP, vasoactive intestinal peptide.
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Table 4 Summary of somatostatin analogue studies in dumping syndrome
Study Design Treatment Results
Subcutaneous octreotide
Hopman et al. (80) Double-blind, randomized,
controlled study N = 12
Octreotide 50 μg vs
placebo before OGTT
• Improved symptoms and suppressed postprandial rise
in pulse rate
• Reduced peak insulin and increased nadir glycemia
• Slowed GI transit
Primrose and Johnston (81) Double-blind,
randomized, cross-over,
controlled study N = 10
Octreotide 50 μg or 100 μg
vs placebo before OGTT
• Reduced early dumping and abolished late dumping
symptoms
• Suppressed early dumping-associated changes in
haematocrit and pulse rate
• Inhibited hypoglycemia
Tulassay et al. (82) Double-blind, randomized,
controlled study N = 8
Octreotide 50 μg vs
placebo before OGTT
• Suppressed rise in pulse rate,
haematocrit and plasma levels of VIP
• Prevented postprandial hypoglycemia
• Inhibited rise in plasma insulin and GIP
Geer et al. (83) Double-blind, randomized,
controlled study N = 10
Octreotide 100 μg vs
placebo before OGTT
• Prevented symptom development including late
hypoglycemia before OGTT
• Inhibited rise in plasma levels of glucose, glucagon,
pancreatic polypeptide, neurotensin and insulin
• Slowed gastric emptying and GI transit
Richards et al. (84) Double-blind, randomized,
controlled study N = 6
Octreotide 100 μg vs
placebo before OGTT
• Prevented symptom development
• Induced phase III migrating motor complex in the
small intestine
• Decreased postprandial intestinal motor activity
Gray et al. (85) Double-blind, randomized,
cross-over, controlled
study, N = 9
Octreotide 100 μg vs
placebo before OGTT
• Suppressed symptoms and rise in pulse rate
• Inhibited insulin release
• Prevented hypoglycemia
Hasler et al. (86) Double-blind, randomized,
cross-over, controlled
study, N = 8
Octreotide 50 μg vs
placebo before OGTT
• Suppressed symptoms and rise in pulse rate
• No effect on change in haematocrit, inhibition of insulin
release, prevention of hypoglycemia or gastric emptying rate
Arts et al. (15) Single-arm, open-label
study, N = 30
Octreotide 50 μg for
3 days1
• Suppressed rise in pulse rate and haematocrit
• Inhibited postprandial hypoglycemia and rise in insulin
plasma levels
• Improved early and late dumping symptoms
Vilarrasa et al. (66) Multicenter, retrospective,
systematic, case series,
N = 13
Octreotide 50/100 μg/12 h • 3 patients (23%) had a complete response2
• 5 patients (38.4%) had a partial response3
Long-term Treatment With Subcutaneous Octreotide
Geer et al. (83) Double-blind, randomized,
controlled study, N = 10
Octreotide 100 μg vs
placebo; mean treatment
period, 15 months.
• Provided sustained symptom control
• Resulted in minimal side effects
• Provided stable fasting plasma glucose levels, normal
liver function tests and an average weight gain of 11%
during a 12-month period
• Most patients able to resume employment
Vecht et al. (87) Single-arm, open-label




• Provided early relief of early and late symptoms in all
patients
• Long-term effects less beneficial
• Symptom relief persisted in 80% of patients at 3 months
Didden et al. (88) Single-arm, open-label




• Provided early relief of early and late symptoms in all
patients
• Long-term effects less beneficial
• 47% of patients discontinued therapy because of side
effects or lack of efficacy
Long-Acting Octreotide
Penning et al. (89) Single-arm, open-label
study N = 12
Octreotide LAR 10 mg
every 4 weeks for
6 months vs
subcutaneous octreotide
• Both formulations improved symptoms
• Octreotide LAR was superior at increasing body weight
and improving quality of life
(Continues)
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Somatostatin analogues may be administered subcutane-
ously three times daily as a short-acting formulation or
intramuscularly once every 2 to 4weeks as a long-acting
formulation. Short-acting formulations may be more
effective at improving some dumping symptoms such as
hypoglycemia (15,81–83,85); however, the need for
repeated injections throughout the day is often a major
limitation to the long-term administration of short-acting
formulations. Long-acting formulations are preferred by
patients because of less frequent administration and the
associated improvements in quality of life (15,89). The most
common adverse events associated with somatostatin
analogues are diarrhoea, nausea, steatorrhea, gallstone
formation and pain at the injection site. Despite the
occurrence of steatorrhea, which is generally mild, patients
with dumping syndrome who receive long-term somato-
statin analogue therapy experience a weight gain of
approximately 1% (1). Gallstone formation may influence
treatment selection for dumping syndrome (96,97).
Furthermore, during both short-term treatment and long-
term treatment, a proportion of patients with dumping
syndrome do not respond to currently available somato-
statin analogues (1,15,87–89). Somatostatin analogues
have not received regulatory approval for the treatment of
dumping syndrome.
Pasireotide is a multireceptor-targeted somatostatin
analogue with high affinity for 4 of the 5 somatostatin
receptor subtypes, including sst2 and sst5. The affinity of
pasireotide for sst5 is higher than that of octreotide
(98,99). A recent case report demonstrated that pasireotide
inhibited GLP-1 and insulin release more effectively than
octreotide, resulting in improved control of postprandial
hyperinsulinemic hypoglycemia after a gastric bypass
(100). A pilot study also demonstrated that pasireotide sup-
pressed the increase in pulse rate and late hypoglycemia,
and delayed gastric emptying (90). However, pasireotide
did not demonstrate a significant improvement in dumping
symptoms, and approximately 20% of patients in the pilot
study discontinued treatment because of GI events (90). A
recent phase 2, dose-escalation study evaluated the pharma-
cokinetics, efficacy and safety of subcutaneous pasireotide
followed by long-acting release (LAR) pasireotide in
dumping syndrome (NCT01637272: N = 43) (17,101).
Pasireotide effectively controlled postprandial hypoglyce-
mia and improved changes in pulse rate and haematocrit
in patients with dumping syndrome. Both subcutaneous
and LAR pasireotide were well tolerated, and no new safety
signals were identified (101). Another phase 2 study, which
compared the efficacy, safety and quality of life of LAR
lanreotide versus placebo in dumping syndrome, was re-
cently completed, but no results have been published to date
(NCT01923649) (102).
Other Pharmacologic Interventions (level of evidence: V;
grade of recommendation: D)
Other pharmacologic interventions, such as diazoxide,
nifedipine and exendin 9-39 have also been evaluated for
the management of dumping syndrome. Diazoxide is a
potassium channel activator that inhibits calcium-induced
insulin release. Anecdotal evidence suggests that off-label
diazoxide administered at doses ranging from 100mg to
150mg three times daily may be effective in the treatment
of late dumping symptoms, but no effect on early symptoms
is expected because of its mode of action (103). A recent
multicenter, retrospective, systematic case series reported
that treatment of six patients who developed
Table 4 (Continued)
Study Design Treatment Results
Arts et al. (15) Single-arm, open-label
study N = 30
Octreotide LAR 20 mg for
3 months vs subcutaneous
octreotide 50 μg for 3 days
• Both formulations had a beneficial effect on dumping
symptoms, hypoglycemia and pulse rate
• Subcutaneous octreotide was more effective than
octreotide LAR in improving hypoglycemia
• Octreotide LAR was associated with significantly greater
improvements in quality of life and was preferred relative to
subcutaneous octreotide
Pasireotide
Deloose et al. (90) Double-blind, randomized,
cross-over, controlled
study, N = 9
Pasireotide 300 μg vs
placebo for 2 weeks
• Suppressed increase in pulse rate and late hypoglycemia
• Increased peak glycemia
• Delayed gastric emptying
1Efficacy was determined by comparing assessments performed before and after treatment.
2Complete resolution of hypoglycemic events.
3Fifty percent reduction in the number and severity of hypoglycemic events.
Abbreviations: GI, gastrointestinal; GIP, glucose-dependent insulinotropic polypeptide or gastric inhibitory polypeptide; LAR, long-acting release; OGTT,
oral glucose tolerance test; VIP, vasoactive intestinal peptide.
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Table 5 Summary of surgical re-intervention studies for post-Roux-en-Y gastric bypass in dumping syndrome
Study Patients Procedure Results
Gastric bypass reversal
Patti et al. (103) Case report N = 1 Gastric bypass reversal • Ineffective in reversing hypoglycemia
• Partial pancreatectomy required
Campos et al. (106) Prospective study
N = 5
Gastric bypass reversal, N = 2;
modified sleeve gastrectomy,
N = 3
• No postoperative episodes of neuroglycopenia
• No or minimal hypoglycemic episodes
• Hypocalcemia became responsive to oral replacement
therapy
Lee et al. (107) Case report N = 2 Gastric bypass reversal • Ineffective in reversing hypoglycemia
Vilallonga et al. (108) Retrospective database






• No new episodes of severe hypoglycemia
• 3 patients received a concomitant sleeve gastrectomy
• Severe gastroesophageal reflux disease and/or chronic
diarrhoea reported by some patients
Vilarrasa et al. (66) Multicenter, retrospective,
systematic case series
N = 3
Gastric bypass reversal • Hypoglycemia resolved in 2 patients (67%)
• Hypoglycemia persisted in 1 patient (33%) but was
controlled by alpha-glucosidase inhibitors
Rao et al. (109) Case report N = 1 Laparoscopic gastric
bypass reversal
• Marked reduction in hypoglycemia burden 9 months after
reversal
Carter et al. (110) Retrospective analysis
N = 3
Sleeve gastrectomy • Dumping symptoms and hypoglycemia resolved
• 1 patient developed portal vein thrombus and seroma
• 2 patients were readmitted to hospital and required
supplemental nutrition
Lakdawala et al. (111) Case series N = 5 Laparoscopic conversion
to sleeve gastrectomy
• Dumping syndrome resolved
• No complications were reported




• Dumping symptoms resolved
• After 6 months, the Sigstad’s score decreased to 2 points
• No complications were reported
Huang et al. (113) Case report N = 1 Laparoscopic conversion to
modified duodenal switch
• Dumping symptoms resolved
• No complications were reported
Gastric pouch restriction
Z’graggen et al. (114) Case series N = 101 Gastric pouch downsized; silastic
(Fobi) ring around pouch, n = 6;
adjustable band, n = 4
• No new hypoglycemic episodes
• All had symptomatic improvement (assessed via the
Sigstad score)
de Heide et al. (115) Case report N = 1 Laparoscopic adjustable banding
for pouch dilatation
• Subjective improvement in symptoms
Vilarrasa et al. (66) Multicenter, retrospective,
systematic case series
N = 1
Resection of the ‘candy cane’ roux
limb
• Patient was symptom-free 1 year after procedure
Pancreatic resection
Patti et al. (103) Case series N = 3 Distal pancreatectomy (80%),
n = 2; subtotal pancreatectomy
(85%), n = 1
• 1 patient who previously had an unsuccessful
gastric bypass reversal and distal pancreatic resection
required a total pancreatectomy for recurrent symptoms
• 1 patient had improvements but still experienced
episodes of hypoglycemia
• 1 patient had no hypoglycemic episodes
Clancy et al. (116) Case report N = 2 Distal pancreatectomy (80%),
n = 1; subtotal pancreatectomy
(95%), n = 1
• 80% pancreatectomy2 unsuccessful;
pancreaticoduodenectomy required
• Subtotal pancreatectomy successful
Alvarez et al. (117) Case report N = 1 Distal pancreatectomy • Symptom-free for >10 months
Barbour et al. (118) Retrospective
analysis N = 2
Distal pancreatectomy, n = 1;
duodenum-preserving pancreatic
head resection, n = 1
• Symptoms resolved after distal pancreatectomy
• Patient with pancreatic head resection had persistent
symptoms and underwent distal pancreatectomy
Z’graggen et al. (114) Case series N = 31 Distal pancreatectomy and Fobi
ring around gastric pouch, n = 2;
distal pancreatectomy
(50%–60%) and removal
of pouch band, n = 1
• No new hypoglycemic episodes
(Continues)
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hyperinsulinemic hypoglycemia after bariatric surgery with
diazoxide (168.7 ± 94mg/day orally) resulted in a partial
response (defined as a 50% reduction in the number and
severity of hypoglycemic events) in three patients (50%)
(66). Nifedipine, a calcium channel blocking agent,
successfully controlled persistent hyperinsulinemic hypogly-
cemia in a case report of an adult patient with dumping
syndrome that occurred after gastric bypass surgery (104).
Administration of nifedipine in combination with verapamil
to 10 patients who developed hyperinsulinemic hypoglyce-
mia after bariatric surgery resulted in a partial response in
five patients (50%) (66). Continuous infusion of the GLP-1
receptor antagonist exendin 9-39 has recently been shown
to correct hypoglycemia after gastric bypass, which may
result in a new therapeutic approach for the management
of dumping syndrome. The benefit observed with exendin
9-39 therapy is consistent with the role of GLP-1 in the
development of postprandial hypoglycemia after gastric
bypass (18). Because these pharmacologic interventions
have only been evaluated in small studies, current evidence
supporting their efficacy in dumping syndrome is generally
quite limited.
Surgical re-intervention or continuous enteral
feeding
Despite the availability of several effective therapeutic op-
tions, some patients will continue to experience treatment-
refractory dumping syndrome. Surgical re-intervention or
continuous enteral feeding is additional therapeutic
approaches that can be considered in this situation.
Surgical re-intervention (level of evidence: IV; grade of
recommendation: C)
Most patients with postprandial hypoglycemia after
Roux-en-Y gastric bypass respond to dietary modification
and pharmacologic intervention. However, a subset of
patients with severe post-Roux-en-Y gastric bypass
hypoglycemia may respond inadequately, and surgical
re-intervention may be considered. In general, surgical re-
intervention procedures are largely ineffective, and some
procedures (e.g. pancreatectomy) are rarely performed
because of lack of effectiveness and high morbidity. A study
of patients who underwent partial pancreatectomy because
of noninsulinoma pancreatogenous hypoglycemia
Table 5 (Continued)
Study Patients Procedure Results
Rumilla et al. (119) Case series N = 27 Partial pancreatectomy • 8 patients had recurrent or ongoing mild symptoms
Mathavan et al. (120) Retrospective
study N = 9
Distal pancreatectomy (80%) • 2 patients had complete symptom resolution
• 3 had occasional symptoms
• 2 had frequent symptoms
• 2 patients had severe symptoms refractory to medical
therapy (calcium channel blockers, diazoxide and
octreotide)
• Both patients had extended (95%) pancreatic resection;
1 had resolution of symptoms and symptoms persisted in
the second patient
Vanderveen et al. (105) Retrospective
chart review N = 33
Pancreatic resection • Approximately 40% of patients had moderate or highly
successful surgical outcomes, with an improvement in
hypoglycemic symptoms
Rabiee et al. (121) Case report N = 1 Distal pancreatectomy (85%) • Symptoms resolved but elevated levels of GLP-1 persisted
Ceppa et al. (122) Case report N = 1 Distal pancreatectomy • Hypoglycemia persisted and a total pancreatectomy was
required
Qintar et al. (123) Case report N = 1 Distal pancreatectomy (80%) • Full remission initially after surgery but hypoglycemia
recurred after 6 months
• Hypoglycemia recurrence well-controlled by octreotide
therapy
Lee et al. (107) Case report N = 1 Distal pancreatectomy • Distal pancreatectomy was followed by gastric bypass
reversal
• Gastric bypass reversal was ineffective in reversing
hypoglycemia
Vilarrasa et al. (66) Multicenter, retrospective,
systematic case
series N = 33
Partial pancreatectomy • Hypoglycemia resolved in 2 patients (67%)
1Two additional patients (N = 12) with concomitant pancreatic resection excluded from the gastric pouch restriction subgroup but are included in the pan-
creatic resection subgroup.
2Resection of 80% of the total pancreatic volume starting from the pancreatic tail.
3Roux-en-Y gastric bypass or other malabsorptive procedure.
Abbreviation: GLP, glucagon-like peptide.
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demonstrated that nearly 90% experienced recurrent
symptoms suggestive of hypoglycemia (105). Fewer than
half of patients (48%) were deemed to have achieved a
highly or moderately successful surgical outcome, and
25% experienced no apparent benefit (105).
Various surgical re-interventions have been used,
including gastric tube placement, gastric bypass reversal
with or without concomitant sleeve resection and gastric
pouch restriction (Table 5) (66,103,105–123). A special
consideration is the association between hypoglycemia after
Roux-en-Y gastric bypass and nesidioblastosis that may
result in serious and refractory neuroglycopenic symptoms,
which respond to pancreatic resection and re-re
section (124). Because the development of hyperinsulinemic
hypoglycemia after gastric bypass surgery is not accompa-
nied by islet hyperplasia or increased beta-cell turnover,
nesidioblastosis has not been established as the cause of late
dumping syndrome (125).
As shown in Table 5, approximately 24% of patients who
underwent surgical re-intervention because of refractory
Figure 2 Recommended diagnosis and management strategies for dumping syndrome.
a
Limited evidence only.
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severe post-Roux-en-Y gastric bypass hypoglycemia
received a gastric bypass reversal (66,103,106–113) and ap-
proximately 9% had gastric pouch restriction (66,114,115).
Pancreatic resection, the most commonly reported proce-
dure, was performed in approximately 67% of patients
(66,103,105,107,114,116–123). Some patients underwent
two or more consecutive surgical re-interventions or
combined re-interventions for severe hypoglycemia. The
proportion of patients with symptom resolution after each
procedure was generally higher for gastric bypass reversal
or gastric pouch restriction than for pancreatic resection.
Complications of surgical re-intervention included recurrent
symptoms, diabetes and weight gain. Most surgical re-
intervention studies were relatively small and presumably
included highly selected patients, mean follow-up was short,
and the methodology used to evaluate hypoglycemia was
not consistent. Furthermore, the effectiveness of one
surgical re-intervention procedure relative to another has
not been evaluated in adequately controlled clinical studies.
Conservative management approaches should be pursued
before attempting surgical re-intervention as patients with
dumping syndrome may experience symptomatic improve-
ment over time.
Continuous enteral feeding (level of evidence: V; grade of
recommendation: D)
An additional approach for the management of refractory
dumping syndrome involves the provision of a constant
supply of nutrients via a feeding jejunostomy. Anecdotal ev-
idence suggests that continuous enteral feeding may be ben-
eficial in avoiding dumping symptoms after meal ingestion;
however, this approach is invasive and may impair quality
of life (1,126). Restoring the original nutrient transit route
via placement of a gastric tube in the remnant stomach
was also reported to be effective (127). Standardized liquid
meal administration via a gastric tube demonstrated com-
plete reversal of severe metabolic abnormalities including
hypersecretion of insulin and incretin hormones such as
GLP-1 compared with oral administration (127). The
authors of this publication also restored glucose homeosta-
sis via the placement of a gastric tube in the remnant
stomach of a patient who had undergone gastric bypass sur-
gery (Dr. van Beek, unpublished observation). However, as
these findings are based on individual case reports, clinical
evidence supporting the use of continuous enteral feeding
in the management of dumping syndrome is very limited.
Conclusion
Dumping syndrome is a well-known but under-recognized
complication of esophageal and gastric surgery and is be-
coming increasingly prevalent with the rising incidence of
bariatric surgery. Severe dumping syndrome, in particular,
can result in disabling symptoms that impair quality of life.
No medications are currently approved for the management
of dumping syndrome, and most of the currently available
treatments have considerable limitations, including failure
to target early symptoms and poor tolerability.
Our recommendations for the diagnosis and management
of dumping syndrome are based on available published
clinical information and are presented in Fig. 2. Patients
who have undergone esophageal or gastric surgery should
be monitored for symptoms suggestive of early and late
dumping. Suspected dumping syndrome should preferably
be confirmed using symptom-based questionnaires, glyce-
mia monitoring, or, probably most effectively, in a challenge
using an OGTT or mixed-meal tolerance test. The differen-
tial diagnostic evaluation should also consider other postop-
erative conditions or complications that may present with
similar symptoms. First-line management of dumping
syndrome should focus on dietary modification for 3 to
4weeks, with addition of acarbose treatment for patients
who experience postprandial hypoglycemia. If dietary
modification and acarbose treatment are unsuccessful,
somatostatin analogue therapy should be considered in pa-
tients with dumping syndrome who are experiencing inca-
pacitating symptoms and impairment in quality of life.
Short-acting and long-acting somatostatin analogue therapy
should be attempted for 2weeks and for 2months, respec-
tively. Based on patient preference, long-acting somatostatin
analogue formulations are probably the treatment of choice
because they require less frequent administration and have
less impact on quality of life compared with short-acting so-
matostatin analogues. However, short-acting somatostatin
analogues seem to provide the most rigorous control of
pulse rate and glycemia fluctuations associated with
dumping syndrome. Surgical re-intervention or continuous
gastric/enteral feeding may need to be considered in some
patients with treatment-refractory dumping syndrome, but
the outcomes of these approaches are poorly studied and
tend to be more variable.
Finally, effective management of dumping syndrome
requires close collaboration between specialists trained in
recognizing and treating dumping symptoms, including
those with expertise in gastroenterology, endocrinology,
surgery and nutrition. Given the increase in bariatric proce-
dures and, thereby, the potential for an increase in the prev-
alence of dumping symptoms, prospective clinical studies
are needed to evaluate the occurrence of dumping syndrome
and to assess the effect of early detection and treatment of
clinical symptoms on weight loss and quality of life.
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